DE2541931A1 - Immunologische verbindungen - Google Patents

Immunologische verbindungen

Info

Publication number
DE2541931A1
DE2541931A1 DE19752541931 DE2541931A DE2541931A1 DE 2541931 A1 DE2541931 A1 DE 2541931A1 DE 19752541931 DE19752541931 DE 19752541931 DE 2541931 A DE2541931 A DE 2541931A DE 2541931 A1 DE2541931 A1 DE 2541931A1
Authority
DE
Germany
Prior art keywords
tumor
chloroethyl
bound
agent
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE19752541931
Other languages
German (de)
English (en)
Inventor
David Allen Lewis Davies
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GD Searle LLC filed Critical GD Searle LLC
Publication of DE2541931A1 publication Critical patent/DE2541931A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Metal Rolling (AREA)
  • Peptides Or Proteins (AREA)
DE19752541931 1974-09-20 1975-09-19 Immunologische verbindungen Withdrawn DE2541931A1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB41037/74A GB1509707A (en) 1974-09-20 1974-09-20 Immunological compounds

Publications (1)

Publication Number Publication Date
DE2541931A1 true DE2541931A1 (de) 1976-04-01

Family

ID=10417824

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19752541931 Withdrawn DE2541931A1 (de) 1974-09-20 1975-09-19 Immunologische verbindungen

Country Status (7)

Country Link
JP (1) JPS5161640A (https=)
DE (1) DE2541931A1 (https=)
DK (1) DK141773B (https=)
FR (1) FR2285145A1 (https=)
GB (1) GB1509707A (https=)
NL (1) NL7511089A (https=)
SE (1) SE7510505L (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3513572A1 (de) * 1985-04-16 1986-10-16 Karl Prof. Dr.med. 7302 Ostfildern Theurer Herstellung von praeparaten zur spezifischen beeinflussung der humoralen und zellulaeren immunreaktion
DE4122210A1 (de) * 1991-07-04 1993-01-14 Deutsches Krebsforsch Konjugate aus tumoraktiver verbindung und protein sowie verfahren zu deren herstellung und ihre verwendung

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4067971A (en) * 1976-05-13 1978-01-10 The Procter & Gamble Company Therapeutic composition
JPS54132503A (en) * 1978-04-07 1979-10-15 Kayaku Antibiotic Research Co Immune globulin combined neocarcinostatin
JPS5665828A (en) * 1979-11-02 1981-06-03 Kureha Chem Ind Co Ltd Antitumor agent
JPS5665829A (en) * 1979-11-02 1981-06-03 Kureha Chem Ind Co Ltd Antitumor agent
US4315851A (en) 1978-12-29 1982-02-16 Kureha Kagaku Kogyo Kabushiki Kaisha Pharmaceutical composition having antitumor activity
JPS5592325A (en) * 1978-12-29 1980-07-12 Kureha Chem Ind Co Ltd Antitumor agent and its preparation
DE3167679D1 (en) * 1980-03-31 1985-01-24 Inst Int Pathologie Cellulaire Pharmaceutical forms, their preparation and compositions containing the same
JPS58118520A (ja) * 1982-01-09 1983-07-14 Hidematsu Hirai 抗腫瘍性蛋白複合体およびその製造法
JPS59186924A (ja) * 1983-04-08 1984-10-23 Kureha Chem Ind Co Ltd ヒト免疫グロブリン結合抗腫瘍剤
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
JPS62228025A (ja) * 1985-12-27 1987-10-06 Teijin Ltd 抗体複合体の製造方法
WO1988007553A1 (fr) * 1987-03-26 1988-10-06 Teijin Limited Procede de preparation d'un complexe d'anticorps
US5773435A (en) * 1987-08-04 1998-06-30 Bristol-Myers Squibb Company Prodrugs for β-lactamase and uses thereof
AU649275B2 (en) * 1990-11-06 1994-05-19 Bristol-Myers Squibb Company Prodrugs for beta-lactamase and uses thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3513572A1 (de) * 1985-04-16 1986-10-16 Karl Prof. Dr.med. 7302 Ostfildern Theurer Herstellung von praeparaten zur spezifischen beeinflussung der humoralen und zellulaeren immunreaktion
DE4122210A1 (de) * 1991-07-04 1993-01-14 Deutsches Krebsforsch Konjugate aus tumoraktiver verbindung und protein sowie verfahren zu deren herstellung und ihre verwendung
DE4122210C2 (de) * 1991-07-04 1999-04-01 Deutsches Krebsforsch Konjugate aus tumoraktiver Verbindung und Serumalbumin sowie Verfahren zu deren Herstellung und ihre Verwendung

Also Published As

Publication number Publication date
JPS5161640A (en) 1976-05-28
GB1509707A (en) 1978-05-04
DK422475A (https=) 1976-03-21
DK141773B (da) 1980-06-16
SE7510505L (sv) 1976-03-22
FR2285145A1 (fr) 1976-04-16
DK141773C (https=) 1980-11-03
NL7511089A (nl) 1976-03-23
FR2285145B1 (https=) 1980-05-30

Similar Documents

Publication Publication Date Title
DE2541931A1 (de) Immunologische verbindungen
DE3784720T2 (de) Produkt, praeparat und methode zum bekaempfen der allergien.
DE3788058T2 (de) Zelltoxischer antikörperkomplex und verfahren zu seiner herstellung.
DE69331495T2 (de) Impfstoffe gegen neisseria meningitidis gruppe c
DE3853923T2 (de) Kationisierte antikörper für das austragen durch die blut-gehirn-schranke.
DE3785374T2 (de) Gegen eine Substanz mit niedrigem Molekulargewicht spezifischer Antikörper und Verfahren zu seiner Herstellung mittels kolloidaler Metallteilchen als Träger.
DE69019164T2 (de) Verbessertes meningokokkale polysaccharidkonjugatvakzin.
CH619614A5 (https=)
DE3687779T2 (de) Trichotecenkonjugate.
DE2736223A1 (de) Allergen enthaltende substanzen, verfahren zu ihrer herstellung und ihre verwendung
DE69032662T2 (de) Verfahren und zusammensetzungen zur verbesserung der symptome von sepsis
DE2744983A1 (de) Mehrwertiger antigen-protein-komplex
DE3280408T2 (de) Krebshemmende heilmittel fuer die behandlung von t-leukaemien, bestehend aus der a-kette des rizinus und einem spezifischen monoklonalen antikoerper.
DE69032855T2 (de) Antiidiotypischer antikörper, der eine immunantwort gegen ein glykosphingolipid induziert und seine verwendung
DE3218121A1 (de) Arzneimittel zur tumorbehandlung
DE2805663C3 (https=)
CH655010A5 (de) Pharmazeutischer wirkstoff mit antitumoraktivitaet.
DE3314999A1 (de) Verwendung des diterpen-derivates forskolin zur immunstimulation
DE3788148T2 (de) Monoklonale Antikörper und deren Verwendung.
DE69428969T2 (de) Impfstoff geeignet eine Immunantwort gegen N-Glycolysierte-Gangliosiden hervorzurufen und ihre Anwendung als Antikrebsmittel
DE112011102411T5 (de) Verfahren zur Behandlung von Aufmerksamkeits-Mangel-Hyperaktivitäts-Störung
US4017471A (en) Immunological compounds
DE3875306T2 (de) Immunosuppression bei der auf immunotoxin basierten behandlung von menschen.
DE3751319T2 (de) VERWENDUNG UND ZUSAMMENSETZUNG ZUR VERBESSERUNG DES "TARGETING" VON ANTIKöRPERN, ANTIKöRPERTEILEN, SOWIE KONJUGATE DERSELBEN.
DE2945788A1 (de) Arzneimittel und seine verwendung

Legal Events

Date Code Title Description
8139 Disposal/non-payment of the annual fee